Renal Cell Carcinoma Discrimination through Attenuated Total Reflection Fourier Transform Infrared Spectroscopy of Dried Human Urine and Machine Learning Techniques.

Journal: International journal of molecular sciences
PMID:

Abstract

Renal cell carcinoma (RCC) is the sixth most common cancer in men and is often asymptomatic, leading to incidental detection in advanced disease stages that are associated with aggressive histology and poorer outcomes. Various cancer biomarkers are found in urine samples from patients with RCC. In this study, we propose to investigate the use of Attenuated Total Reflection-Fourier Transform Infrared Spectroscopy (ATR-FTIR) on dried urine samples for distinguishing RCC. We analyzed dried urine samples from 49 patients with RCC, confirmed by histopathology, and 39 healthy donors using ATR-FTIR spectroscopy. The vibrational bands of the dried urine were identified by comparing them with spectra from dried artificial urine, individual urine components, and dried artificial urine spiked with urine components. Urea dominated all spectra, but smaller intensity peaks, corresponding to creatinine, phosphate, and uric acid, were also identified. Statistically significant differences between the FTIR spectra of the two groups were obtained only for creatinine, with lower intensities for RCC cases. The discrimination of RCC was performed through Principal Component Analysis combined with Linear Discriminant Analysis (PCA-LDA) and Support Vector Machine (SVM). Using PCA-LDA, we achieved a higher discrimination accuracy (82%) (using only six Principal Components to avoid overfitting), as compared to SVM (76%). Our results demonstrate the potential of urine ATR-FTIR combined with machine learning techniques for RCC discrimination. However, further studies, especially of other urological diseases, must validate this approach.

Authors

  • Bogdan Adrian Buhas
    Department of Urology, Medicover Hospital, 323T Principala St., 407062 Suceagu, Romania.
  • Lucia Ana-Maria Muntean
    Department of Medical Education, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Victor Babes St., 400347 Cluj-Napoca, Romania.
  • Guillaume Ploussard
    Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Bogdan Ovidiu Feciche
    Faculty of Medicine and Pharmacy, University of Oradea, 1 Universitatii St., 410087 Oradea, Romania.
  • Iulia Andras
    ORSI Academy, Melle, Belgium.
  • Valentin Toma
    Department of Nanobiophysics, MedFuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 4-6 Pasteur St., 400337 Cluj-Napoca, Romania.
  • Teodor Andrei Maghiar
    Faculty of Medicine and Pharmacy, University of Oradea, 1 Universitatii St., 410087 Oradea, Romania.
  • Nicolae Crisan
    Department of Urology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Rareș-Ionuț Știufiuc
    Department of Nanobiophysics, MedFuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 4-6 Pasteur St., 400337 Cluj-Napoca, Romania.
  • Constantin Mihai Lucaciu
    Department of Pharmaceutical Physics-Biophysics, Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, 6 Pasteur St., 400349 Cluj-Napoca, Romania.